Sino Biopharmaceutical (HKG:1177) submitted a new indication application to Chinese medical products regulators for its anlotinib hydrochloride capsule combination with penpulimab injection for hepatocellular carcinoma or liver cancer.
The application comes after Sino Biopharm completed its interim analysis of its phase 3 clinical study for the drug combination, according to a Thursday filing with the Hong Kong Exchange.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。